Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.76 |
| ▸ | METAP1 | P53582 | 3/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860892 | 0.86 | ACHE (1.00) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL29894949 | 0.86 | ACHE (1.00) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL4707087 | 0.84 | ACHE (0.56) | ACHEMETAP1CYP19A1 | |
| SCHEMBL630841 | 0.83 | ACHE (0.58) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL23181421 | 0.83 | METAP1 (0.60) | ACHEMETAP1CYP19A1ALDH1A1KDM4E | |
| SCHEMBL31189156 | 0.81 | METAP1 (0.58) | ACHEMETAP1CYP19A1ALDH1A1KDM4E | |
| SCHEMBL4462617 | 0.81 | METAP1 (0.58) | ACHEMETAP1CYP19A1ALDH1A1KDM4E | |
| SCHEMBL316628 | 0.81 | METAP1 (0.58) | ACHEMETAP1CYP19A1ALDH1A1KDM4E | |
| SCHEMBL14286892 | 0.81 | ACHE (0.55) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL7573550 | 0.79 | METAP1 (0.56) | ACHEMETAP1CYP19A1ALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479813-B2 | Method of therapeutically treating cancer | ADT PHARMACEUTICALS, LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| CN-113121338-B | Synthetic method of alpha-hydroxy-beta-keto acid ester compound | 浙江工业大学 | 2022-10-28 | — | — | CN | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| EP-4053105-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT Pharmaceuticals, LLC (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2022-08-09 | — | — | US | disclosed |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | ADT PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10981886-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10975054-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| EP-1000950-A2 | Novel indanylidene compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-17 | — | — | EP | disclosed |
| EP-0587107-B1 | Process for the preparation of substituted indanones | HOECHST AG (DE) | 1996-08-14 | — | — | EP | disclosed |
| EP-0568879-B1 | Process for the preparation of substituted indanones and their use | HOECHST AG (DE) | 1996-07-17 | — | — | EP | disclosed |
| US-5360936-A | Process for the preparation of substituted indanones | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-01 | — | — | US | disclosed |
| US-5329050-A | Process for the preparation of substituted indanones, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-07-12 | — | — | US | disclosed |
| EP-0587107-A1 | Process for the preparation of substituted indanones | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-16 | — | — | EP | disclosed |
| EP-0568879-A1 | Process for the preparation of substituted indanones and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-11-10 | — | — | EP | disclosed |
| EP-0181145-B1 | HETEROCYCLIC COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-01-31 | — | — | EP | disclosed |
| US-4755511-A | Tricyclic pyridazinone compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-07-05 | — | — | US | disclosed |
| EP-0181145-A2 | Heterocyclic compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | ACHE 982/4885METAP1 4480/4885CYP19A1 91/4885 |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | KRAS, NRAS, HRAS | ACHE 3687/4885METAP1 3373/4885CYP19A1 904/4885 |
| US-12479813-B2 | Method of therapeutically treating cancer | RECQL, RDX, RNASE1 | ACHE 1258/4885METAP1 3949/4885CYP19A1 1131/4885 |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | ACHE 982/4885METAP1 4480/4885CYP19A1 91/4885 |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | ACHE 982/4885METAP1 4480/4885CYP19A1 91/4885 |
| US-10981886-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | ACHE 982/4885METAP1 4480/4885CYP19A1 91/4885 |
| US-10975054-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | ACHE 982/4885METAP1 4480/4885CYP19A1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.